Actimed Competitors

Founded in 1983, the American Institute for Preventive Medicine is an award winning, internationally recognized authority on the development and implementation of health promotion, wellness, medical self-care, and disease management programs and publications. The Institute is one of the first five companies to receive URAC accreditation for comprehensive wellness. We have helped over 13,000 organizations reduce health care costs and absenteeism, while helping over 15 million employees or members improve their health and well being. Our products educate, motivate, and change behavior.

MedExpert is The Medical Decision Company. MedExpert’s mission is to improve lives through the timely exchange, understanding, and implementation of current, unbiased, and accurate medical and health information. This mission is built upon the fundamental belief that every person—regardless of language, education, or station in life—deserves today’s finest medical knowledge delivered in a prompt, honest, clear, and respectful manner. By responsibly utilizing the innovative AI-based shared decision-making system IMDS™, or Individual Medical Decision Systems, MedExpert delivers customized, evidence-based information to individuals faced with any medical episode. Armed with the very best medical information and 24/7 individualized support from MedExpert, patients are better equipped to: Understand their medical/health situation Select the right path of treatment Discover alternatives to improve results Receive the right care, at the right time, in the right place MedExpert is the future of health care—keeping pace with change and taking our decades of success to prioritize health, improve lives, and reduce costs now and for generations to come.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Nyloxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Extra Strength, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. See: www.nyloxin.com Nutra Pharma also offers Pet Pain-Away: a product aimed at treating moderate to severe chronic pain in companion animals. Pet Pain-Away is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs and cats. In addition to the Company's OTC products, Nutra pharma is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. In 2015, the company was granted Orphan Designation for it's drug, RPI-78M for the treatment of pediatric Multiple Sclerosis. Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates and joint venture partners.